RESEARCH TRIANGLE PARK – GlaxoSmithKlein CEO Emma Walmsley says the drug giant remains committed to tackling the COVID-19 pandemic while at the same time the firm reported quartertly results that beat expectations for revenues and earnings.
“Responding to the COVID-19 pandemic is at the heart of our purpose as a company and GSK’s portfolio is both highly relevant and needed. We have mobilised efforts across the company and I want to thank all the GSK teams for their outstanding work to make sure our vital medicines, vaccines and everyday health products continue to be available to the people who need them.,” Walmsley said.
“We have also taken action to deploy our science and technologies. Our primary aim is to develop multiple adjuvanted COVID-19 vaccines, and we are working with companies and institutions across the world to do so.
Recent GSK COVID-19 headlines in TechWire
GSK to invest $250M as part of coronavirus vaccine effort with US biotech firm
“Our business performed strongly in the quarter with growth in sales and earnings reflecting good underlying performance and increased demand, including stock-building, for many of our products. Looking ahead, we clearly face a period of considerable uncertainty, but we remain confident in the resilience and sustainability of GSK’s business and our ability to deliver on our long-term priorities of Innovation, Performance and Trust.”
Read the full earnings report online.
GSK employs thousands of people across the Triangle with operations in RTP and a manufacturing plant in Zebulon.
